Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,184.00 by Analysts at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective trimmed by Morgan Stanley from $1,235.00 to $1,184.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada restated an “outperform” rating and set a $1,260.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 22nd. Finally, Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $1,090.24.

Regeneron Pharmaceuticals Stock Up 0.6 %

Shares of REGN stock traded up $5.40 on Friday, reaching $843.60. 1,087,285 shares of the stock were exchanged, compared to its average volume of 768,492. The business’s 50 day moving average price is $1,058.43 and its 200 day moving average price is $1,038.87. The company has a market capitalization of $93.00 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 2.88 and a beta of 0.15. Regeneron Pharmaceuticals has a twelve month low of $783.57 and a twelve month high of $1,211.20. The company has a current ratio of 5.99, a quick ratio of 4.62 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter last year, the business posted $8.79 EPS. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 37.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. Sachetta LLC grew its stake in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $28,000. Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.